Cell Biotech
쎌바이오텍 · 049960
Health Care Pharmaceuticals · KOSDAQ
Market cap US$113.1M (₩156B)
Overview
Cell Biotech develops oral treatments for colorectal cancer using live bacteria, specifically, a genetically engineered lactic-acid bacterium designed to produce an anti-cancer protein directly inside the gut.
The company is listed on KOSDAQ, South Korea's tech and small-cap exchange, and its pipeline candidate is currently in a Phase One clinical trial at Seoul National University Hospital. Its drug-development work builds directly on its existing expertise in cultivating and commercialising lactic-acid bacterial strains, which it has developed over more than three decades.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$39M
- FY2024US$36.2M
- FY2025US$38.5M
Operating profit
- FY2023US$1.6M
- FY2024US$4.9M
- FY2025US$5.7M
Net income
- FY2023US$4.6M
- FY2024US$11M
- FY2025US$7.3M
Key ratios (FY2025)
Why it matters
The company has obtained a GMP (good manufacturing practice) licence for a biologics facility, allowing it to produce clinical-trial drug supply in-house using its own bacterial fermentation technology.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?